Irritable Bowel Syndrome

被引:451
作者
Ford, Alexander C. [1 ,2 ]
Lacy, Brian E. [3 ]
Talley, Nicholas J. [4 ,5 ,6 ]
机构
[1] Univ Leeds, Leeds Inst Biomed & Clin Sci, Leeds, W Yorkshire, England
[2] St James Univ Hosp, Leeds Gastroenterol Inst, Leeds, W Yorkshire, England
[3] Dartmouth Hitchcock Med Ctr, Sect Gastroenterol & Hepatol, Lebanon, NH 03766 USA
[4] Univ Newcastle, Fac Hlth & Med, Newcastle, NSW, Australia
[5] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[6] Karolinska Inst, Stockholm, Sweden
关键词
PLACEBO-CONTROLLED TRIAL; LOW FODMAP DIET; DOUBLE-BLIND; GENERAL-POPULATION; REDUCES SYMPTOMS; CELIAC-DISEASE; CLINICAL-TRIAL; RISK-FACTORS; CONSTIPATION; METAANALYSIS;
D O I
10.1056/NEJMra1607547
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The irritable bowel syndrome (IBS) is a chronic and sometimes disabling functional bowel disorder.(1,2) Traditionally, this functional diagnostic label has been applied when no obvious structural or biochemical abnormalities are found, but emerging evidence suggests that distinct pathophysiological disturbances may account for the symptoms and that IBS is unlikely to be one disease or merely a psychiatric (somatosensory) disorder.(2) The Rome IV criteria, 1 derived from a consensus process by a multinational group of experts in functional gastrointestinal disorders, constitute the current standard for diagnosing IBS. According to these criteria, IBS is diagnosed on the basis of recurrent abdominal pain related to defecation or in association with a change in stool frequency or form (Table 1). Bloating is a common accompanying symptom. Symptoms must be chronic, occurring at least once per week, on average, in the previous 3 months, with a duration of at least 6 months. IBS negatively affects quality of life and work productivity. It has been estimated that patients would give up 10 to 15 years of life expectancy for an instant cure of the disease.(3) The prevalence of IBS in the United States is between 7% and 16%, and the condition is most common in women and young people.(4) Direct costs associated with IBS in the United States have been estimated, conservatively, at more than $1 billion.(5) Thus, diagnosing IBS accurately, minimizing invasive investigations, and recommending effective treatment have an important role in efforts to reduce the societal and economic effects of the disease.
引用
收藏
页码:2566 / 2578
页数:13
相关论文
共 76 条
[41]   A sustained hypothalamic-pituitary-adrenal axis response to acute psychosocial stress in irritable bowel syndrome [J].
Kennedy, P. J. ;
Cryan, J. F. ;
Quigley, E. M. M. ;
Dinan, T. G. ;
Clarke, G. .
PSYCHOLOGICAL MEDICINE, 2014, 44 (14) :3123-3134
[42]   Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia [J].
Koloski, N. A. ;
Jones, M. ;
Weltman, M. ;
Kalantar, J. ;
Bone, C. ;
Gowryshankar, A. ;
Walker, M. M. ;
Talley, N. J. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2015, 27 (09) :1317-1325
[43]   A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D) [J].
Lam, Ching ;
Tan, Wei ;
Leighton, Matthew ;
Hastings, Margaret ;
Lingaya, Melanie ;
Falcone, Yirga ;
Zhou, Xiaoying ;
Xu, Luting ;
Whorwell, Peter ;
Walls, Andrew F. ;
Zaitoun, Abed ;
Montgomery, Alan ;
Spiller, Robin .
GUT, 2016, 65 (01) :91-99
[44]   Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome [J].
Lembo, Anthony ;
Pimentel, Mark ;
Rao, Satish S. ;
Schoenfeld, Philip ;
Cash, Brooks ;
Weinstock, Leonard B. ;
Paterson, Craig ;
Bortey, Enoch ;
Forbes, William P. .
GASTROENTEROLOGY, 2016, 151 (06) :1113-1121
[45]   Eluxadoline for Irritable Bowel Syndrome with Diarrhea [J].
Lembo, Anthony J. ;
Lacy, Brian E. ;
Zuckerman, Marc J. ;
Schey, Ron ;
Dove, Leonard S. ;
Andrae, David A. ;
Davenport, J. Michael ;
McIntyre, Gail ;
Lopez, Rocio ;
Turner, Lisa ;
Covington, Paul S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03) :242-253
[46]   Immune activation in patients with irritable bowel syndrome [J].
Liebregts, Tobias ;
Adam, Birgit ;
Bredack, Christoph ;
Roth, Alexander ;
Heinzel, Susanne ;
Lester, Sue ;
Downie-Doyle, Sarah ;
Smith, Eric ;
Drew, Paul ;
Talley, Nicholas J. ;
Holtmann, Gerald .
GASTROENTEROLOGY, 2007, 132 (03) :913-920
[47]   Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis [J].
Lovell, Rebecca M. ;
Ford, Alexander C. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (07) :712-+
[48]   Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial [J].
Madisch, A ;
Holtmann, G ;
Plein, K ;
Hotz, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (03) :271-279
[49]   Bowel Disorders [J].
Lacy, Brian E. ;
Mearin, Fermin ;
Chang, Lin ;
Chey, William D. ;
Lembo, Anthony J. ;
Simren, Magnus ;
Spiller, Robin .
GASTROENTEROLOGY, 2016, 150 (06) :1393-+
[50]   THE IRRITABLE-BOWEL-SYNDROME - LONG-TERM PROGNOSIS AND THE PHYSICIAN-PATIENT INTERACTION [J].
OWENS, DM ;
NELSON, DK ;
TALLEY, NJ .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (02) :107-+